SPRY ARS Pharmaceuticals PE ratio, current and historical analysis
The current P/E ratio of SPRY cannot be calculated, as the latest EPS of -$0.51 is negative. The most recent PE ratio recorded for ARS Pharmaceuticals was 9.96 in September 2022.
SPRY PE ratio history
How has SPRY's PE ratio performed in the past
Today
N/A
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
ARS Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2023 | N/A | N/A | $5.48 | -$0.57 |
| 2022 | N/A | N/A | $8.53 | -$0.87 |
| 2021 | N/A | N/A | $6.66 | -$0.7 |
| 2020 | N/A | N/A | $46.34 | -$11.33 |
| 2019 | N/A | N/A | N/A | -$36.27 |
| 2018 | N/A | N/A | N/A | -$29.11 |
ARS Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Sep 2024 | N/A | N/A | $14.5 | -$0.51 |
| Jun 2024 | N/A | N/A | $8.51 | -$0.47 |
| Mar 2024 | N/A | N/A | $10.22 | -$0.52 |
| Dec 2023 | N/A | N/A | $5.48 | -$0.57 |
| Sep 2023 | N/A | N/A | $3.78 | -$0.71 |
| Jun 2023 | N/A | N/A | $6.7 | -$0.76 |
| Mar 2023 | N/A | N/A | $6.51 | -$0.79 |
| Dec 2022 | N/A | N/A | $8.53 | -$0.87 |
| Sep 2022 | 9.96 | -78.86% | $5.28 | $0.53 |
| Jun 2022 | 47.11 | N/A | $4.24 | $0.09 |
| Mar 2022 | N/A | N/A | $3.51 | -$0.4 |
| Dec 2021 | N/A | N/A | $6.66 | -$0.7 |
| Sep 2021 | 0.61 | -90.15% | $9.98 | $16.31 |
| Jun 2021 | 6.19 | N/A | $30.89 | $4.99 |
| Mar 2021 | N/A | N/A | $43.63 | -$3.96 |
SPRY average PE ratio chart
What is the average PE ratio of SPRY for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
SPRY PE vs peers
What is SPRY's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| ORMP Oramed Pharmaceuticals Inc | 19.91 | $88.28M |
| OLMA Olema Pharmaceuticals Inc | N/A | $353.53M |
| OMER Omeros Corp | N/A | $529.08M |
| OMGA Omega Therapeutics Inc | N/A | $8.3M |
| ONVO Organovo Holdings Inc | N/A | $5.2M |
| ORIC Oric Pharmaceuticals Inc | N/A | $758.59M |
| SPRY ARS Pharmaceuticals Inc | N/A | $1.22B |
Frequently asked questions
What is ARS Pharmaceuticals's PE ratio?
The current price to earnings ratio of SPRY cannot be determined, as its EPS of -$0.51 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.